Longeveron Inc. (LGVN), on Thursday, announced a positive outcome from its Type B meeting with the U.S. FDA, confirming the regulatory pathway for its investigational cell therapy, laromestrocel (Lomecel-B), as a potential treatment for Alzheimer's disease.
The planned Phase 2/3 pivotal trial will serve as the basis for Biological License Application or BLA submission, pending positive results.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com